Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer, today announced it granted inducement awards on September 30, 2022 (the “Grant Date”) under Adicet’s 2022 Inducement Plan as a material inducement to employment to four individuals hired by Adicet in September 2022. The employees received, in the aggregate, non-qualified stock options to purchase 25,600 shares of Adicet’s common stock with an (…..) Continue reading »
The Latest Press Releases